CJC 1295 is a recurring topic in our peptide coverage. This hub collects every article tagged CJC 1295, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-ranked look at the peptides marketed for sleep — DSIP, MK-677, epitalon, CJC-1295 and ipamorelin. The honest headline: no peptide is a proven insomnia treatment, and the best human data are tiny and decades old.
An evidence-graded review of the peptides marketed for muscle growth and lean mass — follistatin, CJC-1295, ipamorelin, MGF and IGF-1 LR3. The honest 2026 verdict: no peptide has Grade A human muscle-outcome data, and every one is prohibited in sport by WADA.
A clinical, evidence-first ranking of the peptides marketed for the menopause transition — separating the one FDA-approved molecule from the population-borrowed, preclinical, and mechanistically backwards claims.
An evidence-first review of the peptides men buy for muscle, testosterone, libido and recovery — graded honestly by human data, with the FDA and WADA status that marketing leaves out.
An evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
An evidence-first ranking of the GH secretagogues sold for 'growth hormone optimization' — tesamorelin, MK-677, CJC-1295, sermorelin and ipamorelin — separating what raises GH/IGF-1 in humans from what only sounds like it should.
A clinical, evidence-first review of the peptides marketed for fatigue and low energy — elamipretide (SS-31), thymosin alpha-1, MOTS-c, CJC-1295 and ipamorelin. The blunt headline: no peptide has a positive fatigue RCT in healthy people.
An evidence-graded review of the peptides marketed for athletic recovery — BPC-157, ipamorelin, CJC-1295 and TB-500. The honest 2026 verdict: every one is Grade C or D for recovery as an outcome, none is FDA-approved, and all are WADA-banned at all times.
A clinical monograph on ipamorelin — the selective growth-hormone secretagogue famous for the CJC-1295 stack. One human PD study, one failed RCT, and an unsettled 2026 legal status.
A clinical monograph on CJC-1295 without DAC (Mod GRF 1-29) — the short-acting, pulse-preserving GHRH analog. Solid preclinical pharmacology, no human RCT of the no-DAC molecule, and an unsettled 2026 legal status.
CJC 1295 is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged CJC 1295, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.